Prior to Particle Sciences, Dr. Lee had more than 17 years' experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents. His areas of expertise include preformulation, drug delivery, formulation development, analytical sciences, sterile manufacturing, and technology evaluation and development. Dr. Lee was one of the founding members of NanoSystems, a drug delivery company focused on the formulation of water-insoluble drugs using high energy media milling. He maintains strong academic ties, including an appointment as adjunct associate professor of pharmaceutical chemistry at the University of Kansas in 1992, and serving as a reviewer for both the International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.
Mr. Lee will be reporting to Barbara Morgan, general manager, Particle Sciences.
"Robert comes to this position with deep industry experience and has been instrumental in growing Particle Sciences to its current position as a leading pharmaceutical CDMO of complex drug products," said Dr. Morgan.
Particle Sciences, a Lubrizol LifeSciences company, is a drug delivery CDMO, an integrated provider of drug development services and manufacturing, and is FDA registered and DEA licensed. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano‐particulates, drug-eluting devices, solid solutions, lyophilization and others.